Can a new drug help when standard therapy falls short for prostate cancer?

NCT ID NCT07737925

Not yet recruiting Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This phase 2 trial is testing an experimental drug called xaluritamig in men with metastatic castrate-resistant prostate cancer who had only a partial or stable response to lutetium-177 therapy. The goal is to see if xaluritamig can shrink tumors or lower PSA levels. About 30 participants will receive the drug as a short IV infusion and be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called xaluritamig, given as a short IV infusion
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer who have not responded well to standard therapies.
What could go wrong: This is a small early-phase study with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATE RESISTANT PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.